Sign In
Buy IMMP
$0.407
-0.0093 (-2.24%)
At Close: Jun 03, 2026
Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024
08:15am, Thursday, 12'th Dec 2024
SYDNEY, AUSTRALIA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunoth
Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients
03:18pm, Friday, 15'th Nov 2024
Positive results from phase 1 INSIGHT-003 study, using eftilagimod alpha in combination with KEYTRUDA and chemotherapy in treating first-line metastatic non-squamous NSCLC patients. Additional data fr
Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial
11:16am, Thursday, 14'th Nov 2024
On Thursday, Immutep Limited IMMP released data from the INSIGHT-003 Phase 1 trial of eftilagimod alpha (efti) in combination with Merck & Co Inc's MRK Keytruda (pembrolizumab) and chemotherapy for f
Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
08:15am, Thursday, 14'th Nov 2024
Media Release Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and exceeding expectations: Median Overall Survival is 32.9 m
Immutep Quarterly Activities Report Q1 FY25
08:00am, Tuesday, 29'th Oct 2024
SYDNEY, AUSTRALIA, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunoth
Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit
08:00am, Thursday, 10'th Oct 2024
Media Release SYDNEY, AUSTRALIA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel
Immutep: Navigating The Bumps In The Road
09:10am, Monday, 07'th Oct 2024
Immutep Limited (IMMP) has shown underwhelming results in their TACTI-003 trial, raising questions about the efficacy of their lead drug, eftilagimod. Despite the disappointing data, IMMP has a strong
SYDNEY, AUSTRALIA, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immun
Immutep Quarterly Activities Report Q4 FY24
08:00am, Wednesday, 31'st Jul 2024
Media Release Entered into third and most important clinical trial collaboration and supply agreement to date with MSD to evaluate eftilagimod alfa (efti) in combination with KEYTRUDA® (pembrolizumab
Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals
09:42am, Monday, 15'th Jul 2024
Immutep (IMMP) jumps 15% on positive results from a late-stage study evaluating its candidate, efti, in combination with Keytruda to treat first-line head and neck squamous cell carcinoma patients.
Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression
06:40pm, Thursday, 11'th Jul 2024
Media Release Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST 1.1, among the highest recorded for a treatment appro
Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results
08:00am, Wednesday, 03'rd Jul 2024
Company to Host Webcast on 12th July at 9am AEST (7pm ET, 11 July) SYDNEY, AUSTRALIA, July 03, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a
Prima BioMed (IMMP) Loses -34.84% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:35am, Friday, 28'th Jun 2024
The heavy selling pressure might have exhausted for Prima BioMed (IMMP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analys
Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer
08:00am, Tuesday, 25'th Jun 2024
Media Release SYDNEY, AUSTRALIA, June 25, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel
Immutep successfully completes institutional placement and institutional component of entitlement offer
06:00am, Wednesday, 05'th Jun 2024
Sydney, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ACN 009 237 889 (ASX: IMM, NASDAQ: IMMP) (Immutep or the Company) is pleased to announce the successful completion of its instituti
